When should we use TNF antagonists in children with rheumatic disease?

Joint Bone Spine

Volumn 74, Issue 1, 2007, Pages 1-3

  Quartier, Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Arthritis; Child; Treatment; Tumor necrosis factor inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRITIS; BACTERIAL INFECTION; CHILD; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENTHESITIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; OSTEOMYELITIS; POLYARTHRITIS; PSORIASIS; RHEUMATIC DISEASE; SPONDYLOARTHROPATHY; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE; UVEITIS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846915381     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.07.001     Document Type: Editorial

References (22)

1. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31 (2004) 390-392
2. Hofer M.F., Mouy R., and Prieur A.M. Juvenile idiopathic arthritides evaluated prospectively in a single center according to the Durban criteria. J Rheumatol 28 (2001) 1083-1090
3. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342 (2000) 763-769
4. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 48 (2003) 1093-1101
5. Horneff G., Schmeling H., Biedermann T., Foeldvari I., Ganser G., Girschick H.J., et al. Paediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 63 (2004) 1638-1644
6. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48 (2003) 218-226
7. Pascual V., Allantaz F., Arce E., Punaro M., and Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005) 1479-1486
8. Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52 (2005) 818-825
9. Sicotte N.L., and Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57 (2001) 1885-1888
10. Tubach F., Salmon-Ceron D., and Ravaud P. Mariette X; for the RATIO Study Group. The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNFα therapy. Joint Bone Spine 72 (2005) 456-460
11. Hawrot A.C., Metry D.W., Theos A.J., and Levy M.L. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol 23 (2006) 67-71
12. Tse S.M., Burgos-Vargas R., and Laxer R.M. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52 (2005) 2103-2108
13. Rajaraman R.T., Kimura Y., Li S., Haines K., and Chu D.S. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113 (2006) 308-314
14. Richards J.C., Tay-Kearney M.L., Murray K., and Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33 (2005) 461-468
15. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 48 (2003) 2079-2080
16. Norman R., Greenberg R.G., and Jackson J.M. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol 54 3 Suppl. 2 (2006) S139-S142
17. Deutschmann A., Mache C.J., Bodo K., Zebedin D., and Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics 116 (2005) 1231-1233
18. Tynjala P., Lahdenne P., Vahasalo P., Kautiainen H., and Honkanen V. Impact of anti-TNF therapy on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 65 8 (2006) 1044-1049
19. Pham T., Claudepierre P., Deprez X., Fautrel B., Goupille P., Hilliquin P., et al. Club Rhumatismes et Inflammation, French Society of Rheumatology. Anti-TNFα therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 72 Suppl. 1 (2005) S1-S58
20. Lehman T.J., Schechter S.J., Sundel R.P., Oliveira S.K., Huttenlocher A., and Onel K.B. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr 145 (2004) 856-857
21. Pham T., Guillemin F., Claudepierre P., Luc M., Miceli-Richard C., Fautrel F., et al. TNFα antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. Joint Bone Spine 73 (2006) 547-553
22. Fautrel B., Constantin A., Morel J., Vittecoq O., Cantagrel A., Combe B., et al. Recommendations of the French Society for Rheumatology. TNFα antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73 (2006) 433-441